I'll research VTRS (Viatris) before writing the preview. Let me start gathering recent filings, transcripts, and news.I'll read the most recent earnings materials (Q1 2026 call and release) plus the Q4 2025 call for full-year guidance context.Let me get recent stock price data and news, plus check the Q4 2025 call for full-year guidance framing.Let me check for recent press releases and news around the key July 30 XULANE LO PDUFA date.Let me do a quick web search on the key catalyst (XULANE LO PDUFA) and consensus estimates.I have strong material. Let me quickly review the Q4 2025 call for 2026 guidance drivers and any tariff/manufacturing risk framing.I have comprehensive material. Let me get the recent dividend detail and any consensus estimate quickly.# Viatris (VTRS) — Q2 2026 Earnings Preview Report date: Thursday, August 6, 2026 (before market open); conference call 8:30 a.m. ET
Viatris reports Q2 into strength: the stock is near 52-week highs after a Q1 blowout, management has effectively teased a guidance raise, and one of the year's key catalysts — the Gwyn Lo contraceptive patch — was approved by the FDA on July 29, just a week before the print. The question is less "will the quarter be fine" and more "how much of the good news is already in the stock, and does management finally raise the full-year bar?"
At Q1, Viatris reaffirmed rather than raised, despite a strong start. The framework:
| Metric | 2026 Guidance | Midpoint |
|---|---|---|
| Total revenues | $14.45B – $14.95B | ~$14.70B |
| Adjusted EBITDA | $4.15B – $4.45B | ~$4.30B |
| Adjusted EPS | $2.33 – $2.47 | ~$2.40 |
| FCF (ex- transaction/restructuring) | $1.95B – $2.35B | ~$2.15B |
Guidance implies only ~2% growth off 2025 ($14.3B revenue / $4.2B EBITDA / $2.35 EPS), yet Q1 already ran at +3% revenue / +10% EBITDA / +14% EPS operationally. Management explicitly said it believes it is "well positioned to meet or potentially exceed" the outlook, and raised its Greater China assumption to mid-to-high single digits (from low single digits). The single biggest swing factor Wednesday is whether management raises FY guidance. A reaffirm-only after another strong quarter could disappoint a stock that has run 40%+.
Phasing note: ~52% of full-year revenue/EBITDA/EPS is weighted to H2, so a Q2 that looks only "in line" isn't necessarily a negative — new-product ramp and launches are back-half loaded.
China was the swing factor in Q1, growing +18% operationally (with e-commerce sales more than doubling) — well ahead of the initial ~3% full-year plan. Management attributes this to an aging population, cardiovascular demand, and years of investment in retail/e-commerce channels that de-risk exposure to hospital-based VBP (volume-based procurement) policy. Watch for: - Whether the ~mid-to-high-single-digit pace held in Q2. - Any commentary on VBP/policy risk — management insists there will be "no policy change this year," but this remains the most unpredictable variable in the model.
This is a heavy catalyst year (6 regulatory decisions targeted). Status check going into the print: - Gwyn Lo (low-dose estrogen weekly contraceptive patch, fka "XULANE LO") — ✅ APPROVED July 29, 2026, on the July 30 PDUFA date. Commercial availability expected later this year. Watch for launch timing, sales-force sizing (~70 reps for women's health), and pricing color. - Fast-acting meloxicam (acute pain, opioid-sparing) — NDA accepted; a PDUFA date was still pending FDA confirmation at Q1. Any update on the goal date and label (opioid-sparing language placement) is a key watch item. Management frames it as a launch for 2027 and a contributor "into the early 2030s." Sales force ~150–200 reps, specialty/post-op focus. - Phentolamine ophthalmic (presbyopia) — PDUFA Oct 17, 2026. - Japan: Effexor for GAD already approved (March); pitolisant decisions expected 2H; Nefecon (IgA nephropathy) top-line readout expected 1H 2026 — watch for this data. - Complex generics: decisions expected this year on ferric carboxymaltose and rotigotine patch; generic Abilify Maintena approved and slated to launch in the U.S. before year-end. - Longer-term innovative: selatogrel (SOS-AMI) on track for full enrollment by end-2026 (~1,200 pts/month); cenerimod (SLE, OPUS-1/2) fully enrolled, data 1H 2027. These are 2027+ readouts but define the growth story. - New product revenue: tracking to the $450M–$550M full-year target; only $71M booked in Q1, so the ramp is heavily back-half — watch the Q2 figure to confirm the trajectory.
The enterprise-wide strategic review (EWSR) targets ~$650M gross / ~$400M net savings over three years (~50% headcount, up to ~10% workforce reduction), phased ~30% in 2026, ~30% in 2027, ~40% in 2028. Q1 already showed the operating leverage (3% revenue → 10% EBITDA growth). Watch for confirmation that ~$120M of 2026 savings remains on track and any updated margin trajectory commentary for 2027–28.
The fundamentals are pointed the right way: a stabilized-and-growing base, real EBITDA leverage from cost-out, a de-risked Gwyn Lo approval in hand, and ample cash for BD and buybacks. But the stock has already rallied ~40% YTD and sits near highs, and the Street EPS is near the top of guidance — meaning the market is leaning toward an eventual guidance raise. The most important tells on August 6: 1. Does management raise (not just reaffirm) FY2026 guidance? A reaffirm-only is the key risk to a richly-priced stock. 2. Did China stay hot, and how confident is management on 2H policy risk? 3. Meloxicam PDUFA date + Gwyn Lo launch specifics — the near-term pipeline proof points. 4. New-product revenue ramp toward the $450–550M target, plus any BD or permanent-CFO news.
Note: figures above combine Viatris's Q1 2026 release/call and FY2026 guidance with third-party consensus estimates and press reports (Gwyn Lo approval, Aug 3 dividend). Company-reported adjusted metrics are non-GAAP.